ASTELLAS PHARMA INC./ JP3942400007 /
2024-11-07 7:39:08 PM | Chg. -0.040 | Volume | Bid9:55:02 PM | Ask9:55:02 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
10.400EUR | -0.38% | 3,451 Turnover: 36,081.035 |
10.145Bid Size: 481 | 10.460Ask Size: 472 | 18.94 bill.EUR | - | - |
GlobeNewswire
08-14
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08-08
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
GlobeNewswire
04-16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
03-19
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degene...
GlobeNewswire
02-26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
02-07
LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veter...
GlobeNewswire
2023-12-11
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
2023-10-19
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
2023-09-14
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
2023-09-11
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors